Belantamab for AL amyloidosis after prior treatments
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests belantamab mafodotin, a medicine designed to target amyloid-producing abnormal cells, in people with relapsed or refractory AL (light-chain) amyloidosis. It’s aimed at improving blood and organ-related signs of the disease after earlier treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to follow study instructions
- Have AL (light-chain) amyloidosis confirmed by specific lab tests (for example Congo red stain) and typing (like mass spectrometry or immunofluorescence)
- Have measurable disease based on blood tests like M-protein or abnormal free light chain results
- Have at least one organ affected by AL amyloidosis (heart, kidneys, liver, gut, lungs, or certain soft-tissue symptoms) per standard criteria
- Have received earlier key treatments or be unable to use them, and be sufficiently “time-out” from recent therapies
- Have heart function that meets safety thresholds (for example ejection fraction above 35%) and organ blood tests within required ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This Phase 2 study tests belantamab mafodotin in people with multiple myeloma that has come back or is not responding to several prior treatments. It may help shrink the cancer and improve disease control when standard options have already been tried.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.